Aurinia Selects Worldwide for Phase III Lupus Trial

Aurinia Pharma has announced the selection of Worldwide Clinical Trials as its CRO for the AURORA study, a Phase III clinical trial for the treatment of active lupus nephritis.

Read the full release here